{"classes":["DISEASE","MEDICAL DEVICE TECHNOLOGY","CHEMICAL","LAW"],"annotations":[null,null,null,null,null,null,null,["      We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems\r",{"entities":[[108,137,"MEDICAL DEVICE TECHNOLOGY"],[142,145,"MEDICAL DEVICE TECHNOLOGY"]]}],["for use by people with diabetes and by healthcare providers. We received approval from the United States (U.S.) Food and Drug Administration, or FDA, and\r",{"entities":[[23,31,"DISEASE"],[112,140,"LAW"],[145,148,"LAW"]]}],["commercialized our first product in 2006. We launched our latest generation system, the DexCom G6® integrated Continuous Glucose Monitoring System, or G6,\r",{"entities":[[110,146,"MEDICAL DEVICE TECHNOLOGY"],[151,153,"MEDICAL DEVICE TECHNOLOGY"]]}],["in 2018. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.\r",{"entities":[]}],["\r",{"entities":[]}],["Products\r",{"entities":[]}],["\r",{"entities":[]}],["     DexCom G6®\r",{"entities":[[5,15,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      In March 2018, we obtained marketing authorization from the FDA for the G6 via the de novo process. The G6 is the first type of CGM system permitted by\r",{"entities":[[66,69,"LAW"],[78,80,"MEDICAL DEVICE TECHNOLOGY"],[110,112,"MEDICAL DEVICE TECHNOLOGY"],[134,144,"MEDICAL DEVICE TECHNOLOGY"]]}],["the FDA to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing\r",{"entities":[[4,7,"LAW"],[93,114,"MEDICAL DEVICE TECHNOLOGY"],[134,158,"MEDICAL DEVICE TECHNOLOGY"]]}],["systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. G6 and substantially equivalent devices of this generic\r",{"entities":[[9,22,"MEDICAL DEVICE TECHNOLOGY"],[24,44,"MEDICAL DEVICE TECHNOLOGY"],[82,102,"MEDICAL DEVICE TECHNOLOGY"],[103,105,"MEDICAL DEVICE TECHNOLOGY"]]}],["type that may later receive marketing authorization are referred to as integrated continuous glucose monitoring systems, or iCGMs, and have been classified as\r",{"entities":[[71,119,"MEDICAL DEVICE TECHNOLOGY"],[124,129,"MEDICAL DEVICE TECHNOLOGY"]]}],["Class II devices by the FDA. Along with this classification, the FDA established criteria, called special controls, which outline requirements for assuring CGM\r",{"entities":[[0,16,"LAW"],[24,28,"LAW"],[65,68,"LAW"],[156,159,"MEDICAL DEVICE TECHNOLOGY"]]}],["accuracy, reliability and clinical relevance, and which also describe the type of studies and data required to demonstrate acceptable CGM performance. The G6 is\r",{"entities":[[134,137,"MEDICAL DEVICE TECHNOLOGY"],[155,157,"MEDICAL DEVICE TECHNOLOGY"]]}],["designed to allow our transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient’s compatible mobile device, including\r",{"entities":[[68,81,"MEDICAL DEVICE TECHNOLOGY"]]}],["iPhone®, iPod touch®, iPad®, and certain Android® mobile devices. A patient’s glucose data can also be displayed on wearable devices, like the Apple Watch® and\r",{"entities":[[78,90,"DISEASE"]]}],["Wear OS by Google devices. The G6 transmitter has a labeled useful life of three months. Data from the G6 can be integrated with DexCom CLARITY®, our\r",{"entities":[[31,45,"MEDICAL DEVICE TECHNOLOGY"],[103,105,"MEDICAL DEVICE TECHNOLOGY"]]}],["cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management. In the United States, the G6 is\r",{"entities":[[152,154,"MEDICAL DEVICE TECHNOLOGY"]]}],["covered by Medicare as well as those commercial insurers that reimburse for the DexCom G5 Mobile Continuous Glucose Monitoring System, subject to\r",{"entities":[[80,133,"MEDICAL DEVICE TECHNOLOGY"]]}],["satisfaction of certain eligibility and coverage criteria.\r",{"entities":[]}],["\r",{"entities":[]}],["      In June 2018, we received Conformité Européenne Marking, or CE Mark, approval for the G6, which allows us to market the system in the European Union\r",{"entities":[[32,61,"LAW"],[66,73,"LAW"],[92,94,"MEDICAL DEVICE TECHNOLOGY"]]}],["and the countries in Asia and Latin America that recognize the CE Mark, as well as New Zealand, though certain countries may require compliance with certain\r",{"entities":[[63,70,"LAW"]]}],["local administrative requirements and/or additional marketing authorizations (for example, the inclusion of medical devices on the Australian Register of\r",{"entities":[]}],["Therapeutic Goods in Australia).\r",{"entities":[]}],["\r",{"entities":[]}],["      In October 2019, we also received marketing authorization from the FDA for the DexCom G6 Pro, or G6 Pro, which allows healthcare professionals to\r",{"entities":[[73,76,"LAW"],[85,98,"MEDICAL DEVICE TECHNOLOGY"],[103,109,"MEDICAL DEVICE TECHNOLOGY"]]}],["purchase the G6 for use with their patients. The G6 Pro has many of same features as the G6 and is intended for healthcare professionals to use with their patients\r",{"entities":[[13,15,"MEDICAL DEVICE TECHNOLOGY"],[49,55,"MEDICAL DEVICE TECHNOLOGY"],[89,91,"MEDICAL DEVICE TECHNOLOGY"]]}],["ages two years and up. The G6 Pro may be used in a blinded or unblinded mode for up to 10 days.\r",{"entities":[[27,33,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["\r",{"entities":[]}],["                                                                                  3\r",{"entities":[]}],["\f     For the G6, the sensor is inserted by the user and is intended to be used continuously for up to 10 days, after which it may be replaced with a new disposable\r",{"entities":[[14,16,"MEDICAL DEVICE TECHNOLOGY"]]}],["sensor. Our transmitter is reusable until it reaches the end of its use life. Our receiver is also reusable. As we establish an installed base of customers using our\r",{"entities":[[12,23,"MEDICAL DEVICE TECHNOLOGY"],[82,90,"MEDICAL DEVICE TECHNOLOGY"]]}],["products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors.\r",{"entities":[[101,119,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["       The G6 carries forward important features of prior generation DexCom CGM systems:\r",{"entities":[[11,13,"MEDICAL DEVICE TECHNOLOGY"],[69,87,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["   •    Continuous glucose readings. Automatically sends glucose readings to a DexCom receiver or compatible mobile device every five minutes.\r",{"entities":[[19,36,"CHEMICAL"],[57,73,"CHEMICAL"]]}],["   •    Mobile app and sharing. Compatibility with mobile device applications allows for sharing glucose information with other people for added support and\r",{"entities":[[97,116,"CHEMICAL"]]}],["        care coordination.\r",{"entities":[]}],["   •    Customizable alarms and alerts. Personalized alert schedule immediately warns the user of pending dangerous high and low blood sugars.\r",{"entities":[[129,141,"CHEMICAL"]]}],["       The G6 also has a number of new or improved features compared to our prior generation devices:\r",{"entities":[[11,13,"MEDICAL DEVICE TECHNOLOGY"]]}],["   •    Finger stick elimination. No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for use.\r",{"entities":[[37,50,"MEDICAL DEVICE TECHNOLOGY"],[81,89,"DISEASE"]]}],["   •    Easy sensor application. Complete redesign of the sensor applicator allows for one-touch, simple self-insertion.\r",{"entities":[]}],["   •    Discreet and low profile. A redesigned transmitter with a 28% lower profile than the previous generation DexCom CGM system makes the device\r",{"entities":[[113,130,"MEDICAL DEVICE TECHNOLOGY"]]}],["        comfortable and easy to wear under clothing.\r",{"entities":[]}],["   •    Medication blocking. New feature allows for more accurate glucose readings without interference from common medications taken at typical indication\r",{"entities":[[66,82,"CHEMICAL"]]}],["        doses, such as acetaminophen.\r",{"entities":[[23,36,"CHEMICAL"]]}],["   •    Predictive low alert. New alert feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.\r",{"entities":[[68,80,"DISEASE"],[124,135,"CHEMICAL"]]}],["   •    Extended 10-day sensor. Up to 10-day sensor use allows for 43% longer wear than previous generation DexCom CGM systems.\r",{"entities":[[115,126,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["     Other than with respect to the foregoing, the G6 is equivalent to our prior generation CGM systems in its technical capabilities and its indications. Since the\r",{"entities":[[51,53,"MEDICAL DEVICE TECHNOLOGY"],[92,103,"MEDICAL DEVICE TECHNOLOGY"]]}],["G6 is classified by the FDA as a Class II device, it is subject to special controls and modifications of, or revisions to, the device may be made under the 510(k)\r",{"entities":[[24,27,"LAW"],[33,48,"LAW"]]}],["process.\r",{"entities":[]}],["\r",{"entities":[]}],["       DexCom G5® Mobile\r",{"entities":[[7,24,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      In August 2015, we received approval from the FDA for the DexCom G5 Mobile Continuous Glucose Monitoring System, also referred to as the G5 Mobile.\r",{"entities":[[52,55,"LAW"],[64,117,"MEDICAL DEVICE TECHNOLOGY"],[143,152,"MEDICAL DEVICE TECHNOLOGY"]]}],["The G5 Mobile is designed to allow our transmitter to run the Software 505 algorithm, and to communicate directly to a patient’s compatible mobile device,\r",{"entities":[[4,13,"MEDICAL DEVICE TECHNOLOGY"],[62,84,"MEDICAL DEVICE TECHNOLOGY"]]}],["including iPhone, iPod touch, iPad, and certain Android mobile devices. The G5 Mobile transmitter has a labeled useful life of three months. Data from the G5\r",{"entities":[[76,97,"MEDICAL DEVICE TECHNOLOGY"],[155,157,"MEDICAL DEVICE TECHNOLOGY"]]}],["Mobile can be integrated with DexCom CLARITY. In September 2015, we launched the G5 Mobile in certain countries in Europe.\r",{"entities":[[30,45,"MEDICAL DEVICE TECHNOLOGY"],[81,90,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      Similar to the G6, the disposable sensor is inserted by the user and is intended to be used continuously for up to seven days, after which it may be replaced\r",{"entities":[[21,23,"MEDICAL DEVICE TECHNOLOGY"]]}],["with a new sensor. The related transmitter is reusable until it reaches the end of its use life, and the related receiver is also reusable. In December 2016, the FDA\r",{"entities":[[31,42,"MEDICAL DEVICE TECHNOLOGY"],[113,121,"MEDICAL DEVICE TECHNOLOGY"],[162,165,"LAW"]]}],["approved the G5 Mobile as the first CGM system in the United States to have a non-adjunctive indication. The non-adjunctive indication expands the lawfully\r",{"entities":[[13,22,"MEDICAL DEVICE TECHNOLOGY"],[36,46,"MEDICAL DEVICE TECHNOLOGY"]]}],["permitted use of the G5 Mobile as a replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the G5 Mobile only\r",{"entities":[[21,30,"MEDICAL DEVICE TECHNOLOGY"],[51,79,"MEDICAL DEVICE TECHNOLOGY"],[84,92,"DISEASE"],[149,158,"MEDICAL DEVICE TECHNOLOGY"]]}],["requires two finger sticks per day for calibration. In the countries and regions outside of the United States that recognize the CE Mark, as well as the United States\r",{"entities":[[129,136,"LAW"]]}],["and Canada, the G5 Mobile also does not require confirmatory finger sticks when making treatment decisions, although a minimum of two finger sticks a day\r",{"entities":[[16,25,"MEDICAL DEVICE TECHNOLOGY"],[48,74,"MEDICAL DEVICE TECHNOLOGY"]]}],["remain necessary for calibration. Approval of the non-adjunctive indication was also an important and necessary step in enabling people with Medicare to access\r",{"entities":[]}],["CGM.\r",{"entities":[[0,3,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["     Except with respect to the foregoing, the G5 Mobile is functionally equivalent to our earlier generation CGM systems in its technical capabilities and its\r",{"entities":[[47,56,"MEDICAL DEVICE TECHNOLOGY"],[110,121,"MEDICAL DEVICE TECHNOLOGY"]]}],["regulatory requirements and indications.\r",{"entities":[]}],["\r",{"entities":[]}],["       DexCom G4® PLATINUM\r",{"entities":[[7,26,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      The DexCom G4 PLATINUM CGM system, or G4 PLATINUM, replaced our DexCom SEVEN PLUS system beginning in 2012, when it was approved for\r",{"entities":[[10,39,"MEDICAL DEVICE TECHNOLOGY"],[44,55,"MEDICAL DEVICE TECHNOLOGY"],[70,94,"MEDICAL DEVICE TECHNOLOGY"]]}],["up to seven days of continuous use by adults with diabetes. Since 2012, we have marketed the G4 PLATINUM under a CE Mark in the European Union, the\r",{"entities":[[93,104,"MEDICAL DEVICE TECHNOLOGY"],[113,120,"LAW"]]}],["countries in Asia and Latin America that recognize the CE Mark, New Zealand and Australia, and in the United States with approval from the FDA. We received\r",{"entities":[[55,62,"LAW"],[139,143,"LAW"]]}],["approvals for a pediatric indication under the CE Mark in February 2013 and from the FDA in February 2014, enabling us to market and sell this system to persons\r",{"entities":[[47,54,"LAW"],[85,88,"LAW"]]}],["two years old and older who have diabetes. In June 2014, we received approval from the FDA for an expanded indication for the G4 PLATINUM for professional\r",{"entities":[[87,90,"LAW"],[126,137,"MEDICAL DEVICE TECHNOLOGY"]]}],["use, which allows healthcare professionals to purchase the G4 PLATINUM system for use with multiple patients. Healthcare professionals can use the insights\r",{"entities":[[59,77,"MEDICAL DEVICE TECHNOLOGY"]]}],["gained from a G4 PLATINUM professional\r",{"entities":[[14,25,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["\r",{"entities":[]}],["                                                                                   4\r",{"entities":[]}],["\fsession to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and medications\r",{"entities":[]}],["have on their glucose levels. In October 2014, we launched our Software 505 algorithm for the G4 PLATINUM, an algorithm which enabled our systems to\r",{"entities":[[14,29,"CHEMICAL"],[63,85,"MEDICAL DEVICE TECHNOLOGY"],[94,105,"MEDICAL DEVICE TECHNOLOGY"]]}],["achieve a single digit MARD, a measure of the accuracy of continuous glucose monitoring.\r",{"entities":[[23,27,"MEDICAL DEVICE TECHNOLOGY"],[58,87,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["       DexCom Share®\r",{"entities":[]}],["\r",{"entities":[]}],["       In 2015, we received approval from the FDA for the G4 PLATINUM with DexCom Share, or Share, and began commercializing this product in the United\r",{"entities":[[46,49,"LAW"],[58,69,"MEDICAL DEVICE TECHNOLOGY"],[75,87,"MEDICAL DEVICE TECHNOLOGY"]]}],["States in the first quarter of 2015 using a secure wireless connection between a patient’s G4 PLATINUM receiver and an app. We now offer this feature through\r",{"entities":[[91,111,"MEDICAL DEVICE TECHNOLOGY"]]}],["the G6 and the G5 Mobile apps as well as the Share2 app, which works with the G4 PLATINUM receiver with Share. The Share remote monitoring system uses an\r",{"entities":[[4,6,"MEDICAL DEVICE TECHNOLOGY"],[15,29,"MEDICAL DEVICE TECHNOLOGY"],[78,98,"MEDICAL DEVICE TECHNOLOGY"]]}],["app on the patient’s iPhone, iPod touch, iPad or Android mobile device to transmit glucose information to the cloud and then to apps on the mobile devices of up to\r",{"entities":[]}],["five designated recipients, or “followers,” who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet\r",{"entities":[]}],["or cellular connection. A patient’s glucose data can also be displayed on a patient’s or follower’s wearable device, such as the Apple Watch and Wear OS by\r",{"entities":[[36,48,"CHEMICAL"]]}],["Google devices, when used in conjunction with the patient’s or follower’s iPhone or Android mobile device.\r",{"entities":[]}],["\r",{"entities":[]}],["       Data and Insulin Delivery Collaborations\r",{"entities":[]}],["\r",{"entities":[]}],["      We have entered into multiple collaboration agreements that leverage our technology platform to integrate our CGM products with insulin delivery systems.\r",{"entities":[[116,119,"MEDICAL DEVICE TECHNOLOGY"],[134,158,"MEDICAL DEVICE TECHNOLOGY"]]}],["The general purpose of these development and commercial relationships is to integrate our technology into the insulin pump or pen product offerings of the\r",{"entities":[[110,122,"MEDICAL DEVICE TECHNOLOGY"],[126,147,"MEDICAL DEVICE TECHNOLOGY"]]}],["respective partner, enabling the partner’s insulin delivery device to receive and display glucose readings from our transmitter and, in some cases, use the glucose\r",{"entities":[[43,66,"MEDICAL DEVICE TECHNOLOGY"],[90,106,"MEDICAL DEVICE TECHNOLOGY"],[116,127,"MEDICAL DEVICE TECHNOLOGY"]]}],["readings for semi-automated insulin delivery. Currently, we have announced significant insulin delivery partnerships with Eli Lilly, Insulet, Novo Nordisk and\r",{"entities":[[28,45,"CHEMICAL"],[87,103,"CHEMICAL"]]}],["Tandem Diabetes. In addition to these major partners, we are working with other companies that are pursuing varying strategies surrounding semi-automated\r",{"entities":[]}],["insulin delivery and data analytics to improve outcomes and ease-of-use in diabetes management.\r",{"entities":[[0,16,"CHEMICAL"]]}],["\r",{"entities":[]}],["       Verily Collaboration\r",{"entities":[]}],["\r",{"entities":[]}],["     On November 20, 2018, we entered into an Amended and Restated Collaboration and License Agreement with Verily Life Sciences LLC (an Alphabet\r",{"entities":[]}],["Company) and Verily Ireland Limited (collectively, Verily), which we refer to as the Restated Collaboration Agreement. This replaced our original Collaboration\r",{"entities":[]}],["and License Agreement with Verily from August 2015, as amended in October 2016, and eliminated any future royalty obligations under the original agreement.\r",{"entities":[]}],["Pursuant to the Restated Collaboration Agreement, we and Verily have agreed to continue to jointly develop a certain next-generation CGM product, and\r",{"entities":[[0,48,"LAW"]]}],["potentially one or more additional CGM products, for which we will have exclusive commercialization rights.\r",{"entities":[[35,47,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      The Restated Collaboration Agreement also provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and\r",{"entities":[[10,42,"LAW"],[68,85,"LAW"],[93,124,"LAW"]]}],["certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject\r",{"entities":[[109,136,"MEDICAL DEVICE TECHNOLOGY"]]}],["to certain exclusions, which are outside the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily’s other\r",{"entities":[[45,48,"MEDICAL DEVICE TECHNOLOGY"]]}],["intellectual property rights to develop, manufacture, and commercialize those kinds of glucose monitoring products and certain CGM-product companion software\r",{"entities":[[0,21,"LAW"],[87,114,"MEDICAL DEVICE TECHNOLOGY"],[127,157,"MEDICAL DEVICE TECHNOLOGY"]]}],["functionalities. The Restated Collaboration Agreement requires us to use commercially reasonable efforts to develop, launch, and commercialize the CGM\r",{"entities":[[21,53,"LAW"],[147,150,"MEDICAL DEVICE TECHNOLOGY"]]}],["product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of us and\r",{"entities":[]}],["Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus.\r",{"entities":[]}],["\r",{"entities":[]}],["     In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to\r",{"entities":[[105,137,"LAW"]]}],["us and the amendment of the original agreement, we have made upfront and incentive payments, and will make potential future milestone payments upon the\r",{"entities":[]}],["achievement of certain goals, as follows:\r",{"entities":[]}],["\r",{"entities":[]}],["   •     On December 28, 2018, we made an initial payment of $250.0 million in shares of our common stock, calculated under the Restated Collaboration\r",{"entities":[]}],["         Agreement to be 1,840,943 shares of our common stock, allocated between Verily and Onduo, LLC, subject to certain transfer restrictions.\r",{"entities":[]}],["   •     During 2019, we paid $3.2 million for the completion of certain development obligations before the agreed-upon deadline.\r",{"entities":[]}],["   •     Additional milestone payments of up to $275.0 million may become due and payable by us upon the achievement of future product regulatory approval and\r",{"entities":[]}],["         revenue milestones. At our election, we may make these milestone payments in shares of our common stock, also allocated between Verily and Onduo,\r",{"entities":[]}],["         LLC, with the number of shares being calculated based on the same share value that was used for purposes of the initial payment, adjusted for stock splits,\r",{"entities":[]}],["         dividends, and the like, subject to customary closing conditions, including any required antitrust approvals applicable to the issuance of such shares.\r",{"entities":[]}],["         Alternatively, at our election, we may make any of these milestone payments in cash. Any such cash\r",{"entities":[]}],["\r",{"entities":[]}],["                                                                                   5\r",{"entities":[]}],["\f       payment would be equal to the number of shares that would otherwise be issued for the given milestone payment (calculated as described above) multiplied\r",{"entities":[]}],["       by the value of our stock on the date the relevant milestone is achieved, adjusted for stock splits, dividends, and the like.\r",{"entities":[]}],["\r",{"entities":[]}],["      Future Products\r",{"entities":[]}],["\r",{"entities":[]}],["     We plan to develop future generations of technologies focused on improved performance and convenience and that will enable intelligent insulin\r",{"entities":[[140,147,"CHEMICAL"]]}],["administration. We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using,\r",{"entities":[[116,131,"DISEASE"]]}],["people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. We will continue to develop a networked platform\r",{"entities":[[12,24,"DISEASE"],[26,46,"DISEASE"]]}],["with open architecture, connectivity and transmitters capable of communicating with other devices and software systems. We also intend to expand our efforts to\r",{"entities":[]}],["accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient\r",{"entities":[[50,69,"MEDICAL DEVICE TECHNOLOGY"],[74,90,"MEDICAL DEVICE TECHNOLOGY"]]}],["behavior.\r",{"entities":[]}],["\r",{"entities":[]}],["Background\r",{"entities":[]}],["\r",{"entities":[]}],["       Diabetes is a disease with significant adverse consequences for human health throughout the world. The International Diabetes Federation, or IDF, estimates\r",{"entities":[[7,15,"DISEASE"],[110,143,"LAW"],[148,151,"LAW"]]}],["that in 2019, 463 million adults (aged 20-79) around the world had diabetes, including 31 million in the United States. IDF estimates that by 2045, the worldwide\r",{"entities":[[120,123,"LAW"]]}],["incidence of people suffering from diabetes will reach 700 million. According to the Centers for Disease Control and Prevention’s National Vital Statistics Reports\r",{"entities":[]}],["for 2017, diabetes was the seventh leading cause of death by disease in the United States, excluding comorbidities associated with the disease. According to the\r",{"entities":[[10,18,"DISEASE"]]}],["Congressional Diabetes Caucus website, diabetes is the leading cause of kidney failure, adult-onset blindness, lower-limb amputations, and a significant cause of\r",{"entities":[[39,47,"DISEASE"],[72,86,"DISEASE"],[88,109,"DISEASE"]]}],["heart disease, stroke, high blood pressure and nerve damage. According to the IDF, there were an estimated 4.2 million deaths attributable to diabetes globally in\r",{"entities":[[0,13,"DISEASE"],[15,21,"DISEASE"],[23,42,"DISEASE"],[47,60,"DISEASE"]]}],["2019 between the ages of 20 and 79 years. The American Diabetes Association, or ADA, Fast Facts, revised in August 2017, states that diabetes is the primary\r",{"entities":[[42,75,"LAW"],[80,83,"LAW"],[133,141,"DISEASE"]]}],["cause of death for more than 80,000 Americans each year, and contributes to the death of more than 250,000 Americans annually.\r",{"entities":[]}],["\r",{"entities":[]}],["      Among people of all ages, 2017 data indicated the following: An estimated 24.7 million people or 7.6% of the U.S. population had been diagnosed with\r",{"entities":[]}],["diabetes. In addition to those newly diagnosed, the Congressional Diabetes Caucus website reports that every 24 hours there are: 238 amputations in people with\r",{"entities":[[0,9,"DISEASE"]]}],["diabetes, 120 people who enter end-stage kidney disease programs, and 48 people who go blind.\r",{"entities":[[31,55,"DISEASE"]]}],["\r",{"entities":[]}],["      According to the ADA, one in every four healthcare dollars was spent on treating people with diabetes in 2017, and the direct medical costs and indirect\r",{"entities":[[23,26,"LAW"],[99,107,"DISEASE"]]}],["expenditures attributable to diabetes in the United States were an estimated $327 billion, an inflation-adjusted increase of approximately 26% since 2012. Of the\r",{"entities":[]}],["$327 billion in overall expenses, the ADA estimated that approximately $237 billion were direct costs associated with diabetes care, chronic complications and\r",{"entities":[[38,41,"LAW"]]}],["excess general medical costs, and $90 billion were indirect costs. The ADA also found that in 2017, average medical expenditures among people with diagnosed\r",{"entities":[[71,74,"LAW"]]}],["diabetes were 2.3 times higher than for people without diabetes. According to the IDF, 2017 expenditures attributable to diabetes were estimated to be $760 billion\r",{"entities":[[0,8,"DISEASE"],[55,64,"DISEASE"],[82,85,"LAW"],[121,129,"DISEASE"]]}],["globally. The IDF estimates that expenditures attributable to diabetes will grow to $845 billion globally by 2045.\r",{"entities":[[14,17,"LAW"],[62,70,"DISEASE"]]}],["\r",{"entities":[]}],["     Continuous Glucose Monitoring\r",{"entities":[[5,34,"MEDICAL DEVICE TECHNOLOGY"]]}],["\r",{"entities":[]}],["      We believe continuous glucose monitoring has the potential to enable more people with diabetes to achieve and sustain tight glycemic control with minimal\r",{"entities":[[17,46,"MEDICAL DEVICE TECHNOLOGY"],[92,100,"DISEASE"],[130,138,"CHEMICAL"]]}],["disruption to their daily lives.\r",{"entities":[]}],["\r",{"entities":[]}],["      The landmark 1993 Diabetes Control and Complications Trial, or DCCT, demonstrated that improving blood glucose control lowers the risk of developing\r",{"entities":[[19,64,"LAW"],[69,73,"LAW"],[103,124,"CHEMICAL"]]}],["diabetes-related complications by up to 50%. The study also demonstrated that people with Type 1 diabetes achieved sustained benefits with intensive\r",{"entities":[[90,105,"DISEASE"]]}],["management. However, according to an article published in The New England Journal of Medicine in November 2014, in two national registries, only 13% to 15%\r",{"entities":[]}],["of people with diabetes met treatment guidelines for good glycemic control, and more than 20% had very poor glycemic control.\r",{"entities":[[15,23,"DISEASE"],[58,74,"CHEMICAL"],[108,124,"CHEMICAL"]]}],["\r",{"entities":[]}],["      Various clinical studies and real world evidence also demonstrate the benefits of continuous glucose monitoring in the management of Type 1 diabetes and\r",{"entities":[[88,117,"MEDICAL DEVICE TECHNOLOGY"],[139,154,"DISEASE"]]}],["insulin-requiring Type-2 diabetes, when compared to regimens relying on self-monitoring of blood glucose. Results of several early clinical trials established that\r",{"entities":[[18,33,"DISEASE"],[91,105,"CHEMICAL"]]}],["CGM usage was associated with improved glycemic outcomes. For instance, a Juvenile Diabetes Research Foundation, or JDRF, study published in the New\r",{"entities":[[0,3,"MEDICAL DEVICE TECHNOLOGY"],[74,111,"LAW"],[116,120,"LAW"]]}],["England Journal of Medicine in 2008, and the extension phase of the study, published in Diabetes Care in 2009, demonstrated that continuous glucose monitoring\r",{"entities":[[129,158,"MEDICAL DEVICE TECHNOLOGY"]]}],["improved A1c levels and reduced incidence of hypoglycemia for patients over the age of 25 and for all patients of all ages who utilized continuous glucose\r",{"entities":[[45,57,"DISEASE"]]}],["monitoring regularly. In 2016, the first randomized, controlled study focusing solely on the benefit of continuous glucose monitoring for diabetes patients using\r",{"entities":[[104,133,"MEDICAL DEVICE TECHNOLOGY"],[138,146,"DISEASE"]]}],["multiple daily injections insulin therapy showed DexCom CGM system users on multiple daily injections of insulin therapy achieved a one percent average A1c\r",{"entities":[[26,41,"CHEMICAL"],[49,66,"MEDICAL DEVICE TECHNOLOGY"],[105,120,"CHEMICAL"]]}],["reduction after 24 weeks of regular use, compared to their baseline. Study participants also increased time spent in their target\r",{"entities":[]}],["\r",{"entities":[]}],["                                                                                 6\r",{"entities":[]}],["\fA1c range and spent less time in hypoglycemia and hyperglycemia when they used a DexCom CGM system compared to those who used only a standard blood\r",{"entities":[[34,46,"DISEASE"],[51,64,"DISEASE"],[82,99,"MEDICAL DEVICE TECHNOLOGY"]]}],["glucose meter to monitor their glucose. This DIaMonD (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) study is the first-of-its-kind in\r",{"entities":[[0,13,"MEDICAL DEVICE TECHNOLOGY"],[31,39,"CHEMICAL"],[45,132,"LAW"]]}],["demonstrating the impact of CGM only, without insulin pumps or other therapeutic interventions, on A1c and hypoglycemia in participants using a multiple daily\r",{"entities":[[28,31,"MEDICAL DEVICE TECHNOLOGY"],[99,102,"DISEASE"],[107,119,"DISEASE"]]}],["injection insulin regimen.\r",{"entities":[[10,25,"CHEMICAL"]]}],["\r",{"entities":[]}],["      Real-time alerts and multi-device integration further differentiate CGM-based and self-monitoring of blood glucose, or SMBG, based diabetes regimens.\r",{"entities":[[74,129,"MEDICAL DEVICE TECHNOLOGY"]]}],["Alerts triggered by existing or impending abnormal glucose values are associated with less exposure to hypo- and hyperglycemia in large real-world data sets, and\r",{"entities":[[51,65,"CHEMICAL"],[113,126,"CHEMICAL"]]}],["multi-device integration allows some CGM systems to communicate with automated insulin delivery systems. One such automated insulin delivery system that\r",{"entities":[[37,48,"MEDICAL DEVICE TECHNOLOGY"],[69,104,"MEDICAL DEVICE TECHNOLOGY"],[114,147,"MEDICAL DEVICE TECHNOLOGY"]]}],["uses the G6 was studied in a large clinical trial that associated its use with numerous quality-of-life and glycemic benefits.\r",{"entities":[[9,11,"MEDICAL DEVICE TECHNOLOGY"],[29,49,"LAW"],[108,125,"CHEMICAL"]]}],["\r",{"entities":[]}],["      In late 2019, the ADA, in its Standards of Medical Care in Diabetes, recognized CGM as a useful tool in diabetes management, citing level “A” evidence in\r",{"entities":[[24,27,"LAW"],[36,73,"LAW"],[86,89,"MEDICAL DEVICE TECHNOLOGY"],[110,129,"DISEASE"]]}],["Type 1 diabetes and level “B” evidence in Type 2 diabetes and pregnancy. The ADA recommends continued access and use “as close to daily as possible” for\r",{"entities":[[0,15,"DISEASE"],[42,57,"DISEASE"],[77,80,"LAW"]]}],["maximal benefit. We believe Dexcom’s CGM technology contributes to better glycemic outcomes and improved quality of life by allowing informed diabetes\r",{"entities":[[28,51,"MEDICAL DEVICE TECHNOLOGY"],[74,91,"CHEMICAL"]]}],["treatment decisions.\r",{"entities":[]}],["\r",{"entities":[]}],["     A 2019 white paper from IQVIA also outlines the potential benefit offered by use of CGM systems, suggesting that increasing time-in-range to industry\r",{"entities":[[29,34,"LAW"],[89,100,"MEDICAL DEVICE TECHNOLOGY"]]}],["standards for Type 1 and Type 2 insulin-using patients would result in significant cost savings to the economic system and the prevention of major complications.\r",{"entities":[]}],["\r",{"entities":[]}],["      Our current target market consists primarily of people with Type 1 and Type 2 diabetes who utilize insulin pump therapy or who utilize multiple daily insulin\r",{"entities":[[105,125,"MEDICAL DEVICE TECHNOLOGY"]]}],["injections. We continue to target people with Type 2 diabetes on multiple daily injection therapy and expect to expand our target market to include all people with\r",{"entities":[[46,61,"DISEASE"]]}],["diabetes, people with pre-diabetes, people who are obese, people who are pregnant, and people with diabetes in the hospital setting. Although the majority of our\r",{"entities":[[22,34,"DISEASE"],[36,56,"DISEASE"]]}],["revenue has been generated in the United States, we have expanded our operations to include certain countries in Africa, Asia, Europe, Latin America, and the\r",{"entities":[]}],["Middle East, as well as Australia, Canada, and New Zealand.\r",{"entities":[]}],["\r",{"entities":[]}],["Commercial Operations\r",{"entities":[]}],["\r",{"entities":[]}],["      We have built a direct sales organization in the United States, Canada and certain countries in Europe to call on healthcare professionals, including\r",{"entities":[]}],["endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. We believe that focusing\r",{"entities":[[103,133,"MEDICAL DEVICE TECHNOLOGY"]]}],["efforts on these participants is important given the instrumental role they each play in the decision-making process for diabetes therapy. To complement our direct\r",{"entities":[]}],["sales efforts, we have entered into distribution arrangements in the United States and internationally that allow distributors to sell our products. We believe our\r",{"entities":[]}],["direct, highly specialized and focused sales organization and our domestic and international distribution agreements are sufficient for us to support our sales efforts\r",{"entities":[]}],["for at least the next twelve months.\r",{"entities":[]}],["\r",{"entities":[]}],["      Product revenues are generated from the sale of our CGM systems through a direct sales force in the United States, Austria, Canada, Germany, Switzerland\r",{"entities":[[58,69,"MEDICAL DEVICE TECHNOLOGY"]]}],["and the United Kingdom as well as through distribution arrangements in the United States, Australia and New Zealand, and certain countries in Africa, Asia,\r",{"entities":[]}],["Europe, Latin America, and the Middle East.\r",{"entities":[]}],["\r",{"entities":[]}],["Market Opportunity\r",{"entities":[]}],["\r",{"entities":[]}],["Diabetes\r",{"entities":[]}],["\r",{"entities":[]}],["       Diabetes is a chronic, life-threatening disease for which there is no known cure. The disease is caused by the body’s inability to produce or effectively utilize\r",{"entities":[[7,15,"DISEASE"]]}],["the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be\r",{"entities":[[4,20,"CHEMICAL"],[81,94,"CHEMICAL"],[103,110,"CHEMICAL"]]}],["maintained at certain concentrations in the blood in order to permit optimal cell function and health. Normally, the pancreas provides control of blood glucose\r",{"entities":[]}],["levels by secreting the hormone insulin to decrease blood glucose levels when concentrations are too high. In people with diabetes, the body does not produce\r",{"entities":[[24,39,"CHEMICAL"],[52,72,"CHEMICAL"],[122,130,"DISEASE"]]}],["sufficient levels of insulin, or fails to utilize insulin effectively, causing blood glucose levels to rise above normal. This condition is called hyperglycemia and often\r",{"entities":[[21,28,"CHEMICAL"],[79,99,"CHEMICAL"],[147,160,"DISEASE"]]}],["results in acute complications as well as chronic long-term complications such as heart disease, limb amputations, loss of kidney function and blindness. When\r",{"entities":[]}],["blood glucose levels are high, people with diabetes often administer insulin in an effort to decrease blood glucose levels. Unfortunately, insulin administration can\r",{"entities":[[0,20,"CHEMICAL"]]}],["drive blood glucose levels below the normal range, resulting in hypoglycemia. In cases of severe hypoglycemia, people with diabetes risk acute complications,\r",{"entities":[[6,26,"CHEMICAL"],[64,77,"DISEASE"],[97,109,"DISEASE"],[123,131,"DISEASE"]]}]]}